New pill targets hard-to-treat cancers with MAPK mutations
Disease control
Recruiting now
This early-stage study tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. About 230 participants w…
Phase: PHASE1 • Sponsor: Nested Therapeutics, Inc • Aim: Disease control
Last updated May 11, 2026 20:46 UTC